ReviewThe oncologist2013
Current understanding and management of medullary thyroid cancer.
Review in The oncologist, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 121 citations in OpenAlex.
- Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial.The oncologist · 2022Trial
- Targeted therapies in the management of advanced medullary thyroid cancer.The oncologist · 2026Review
- Metastatic Medullary Thyroid Carcinoma Without Identifiable Primary Tumor Within the Thyroid Gland, Presenting with Initial Lymph Node Metastasis Followed by Distant Peritoneal Metastasis: A Case Report of a Rare Phenomenon.Journal of clinical medicine · 2026Article
- Simultaneous medullary thyroid carcinoma and primary non-small cell lung cancer: case report and literature review.Discover oncology · 2025Article
- Cytopathology of follicular and oncocytic follicular thyroid neoplasms: A Bethesda System perspective.Cancer cytopathology · 2025Review
- A novel role for nonactin: interfering with G-quadruplex in RET-driven medullary thyroid cancer.BMC cancer · 2024Article
- Diagnosis of Bone Metastasis due to Medullary Thyroid Cancer WithClinical case reports · 2024Article
- Review
- Correlation ofArchives of endocrinology and metabolism · 2024Article
- Improved Adherence to ATA Medullary Thyroid Cancer Treatment Guidelines.Annals of surgical oncology · 2023Article
- Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study.Thyroid research · 2023Article
- Review
- Clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancer.Clinical & experimental metastasis · 2023Article
- Voltage-Gated Sodium Channel NaCancers · 2023Article
- An unusual cause of chronic diarrhea in a Middle-Aged adult: A diagnostic challenge.Clinical case reports · 2023Article
- [European journal of nuclear medicine and molecular imaging · 2023Article
- Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells?Cancers · 2022Review
- What is the status of immunotherapy in thyroid neoplasms?Frontiers in endocrinology · 2022Review
- Development of Functional Thyroid C Cell-like Cells from Human Pluripotent Cells in 2D and in 3D Scaffolds.Cells · 2021Article
- Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medullary thyroid cancer (MTC) typically accounts for 3%-4% of all thyroid cancers. Although the majority of MTCs are sporadic, 20% of cases are hereditary. Hereditary MTC can be found in multiple endocrine neoplasia 2A or 2B or as part of familial MTC based on a specific germline mutation in the RET proto-oncogene. This article discusses the current approaches available for the diagnosis, evaluation, and management of patients and their family members with suspected MTC. The disease is predominantly managed surgically and typically requires a total thyroidectomy and lymph node dissection. A review of recent guidelines on the extent and timing of surgical excision is discussed. There are not very many effective systemic treatment options for MTC, but several emerging therapeutic targets have promise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.